Could a common drug stop Parkinson's treatment side effect before it starts?

NCT ID NCT01538329

Completed Disease control Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether giving amantadine early in Parkinson's disease, before patients develop involuntary movements from their main medication (L-DOPA), could prevent or delay those movements. Researchers enrolled 210 people with early-stage Parkinson's who had been on L-DOPA for less than a year. Participants received either amantadine or a placebo for 18 months, and the team tracked who developed dyskinesia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: amantadine
What this could lead to: If successful, this could show that starting amantadine early helps prevent or delay the involuntary movements caused by standard Parkinson's medication.
What could go wrong: This is a phase 2 trial with moderate size. The effect may be small or not clinically meaningful, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyskinesias Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

CH Charles Nicolle

Rouen, 76031, France
CH Jean Rougier

Cahors, 46005, France
CH Montauban

Montauban, 82013, France
CH de Narbonne

Narbonne, 11108, France
CHG Aix en Provence

Aix-en-Provence, 13616, France
CHU Clermont-Ferrand

Clermont-Ferrand, 63003, France
CHU Dijon

Dijon, 21079, France
CHU Dupuytren

Limoges, 87042, France
CHU Lille

Lille, 59037, France
CHU de Bordeaux

Bordeaux, 33604, France
CHU de Strasbourg

Strasbourg, France
CHU de Toulouse

Toulouse, 31000, France
CHu de Nantes

Nantes, 44093, France
Hopital Jean Bernard

Poitiers, 86021, France
Hopital Lyon

Lyon, 69003, France
Hopital de la Timone

Marseille, 13385, France
Hopital pitié Salpétriére

Paris, 75013, France
hopital Saint Eloi

Montpellier, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.